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glaucoma visited practitioners more often (+0.74 / year),
had more exams (0.42), and were more likely to be using
drug combinations (+28.5%) and to be hospitalised
(+16.2%). Drugs represented the bulk of the expenses 
followed by exams and ofﬁce visits. Two main clinical
factors contributed to costs: abnormalities of the papilla
due to the presence of glaucoma (+ EURO 96.43) and the
number of treatment switches (+ EURO 127.62 / switch).
These were followed by IOP (+ EURO 7.08 / mmHg) and
VA (+ EURO 41.37 / 2 Lines lost VA). In comparison to
work conducted in the mid-nineties, drug costs increased
while hospital costs decreased, although methodologies
were different. CONCLUSION: Two independent factors
explained the bulk of total cost variance: the presence of
glaucoma and therapy switches. They contributed inde-
pendently in an additive way to total cost. Under isotropic
hypotheses, effective early treatment strategies aimed at
postponing the effects of glaucoma and controlling IOP
are expected to be cost saving in the long-term.
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OBJECTIVE: To assess and to identify the key variables
of the life-long societal net value of glaucoma treatment.
METHODS: A Markov model was used to reproduce the
average discounted cost of glaucoma treatment over 40
years in France on a 47-year-old cohort (52% female).
Clinical states were ﬁrst to fourth line treatment, no treat-
ment, laser, surgery, blindness and death. All patients
started ﬁrst line, went successively to the next line after
failure. After each failure (and always after the fourth
line) patients could have either laser or surgery followed
by no treatment, or a new ﬁrst line treatment. Transition
probabilities and resource utilisation came from of a
cross-sectional study with 5 years retrospective data col-
lection for the glaucoma treatment, and from national
statistics. In-patient and out-patient direct medical costs
and indirect costs were estimated from a societal point 
of view. The discount rate was ﬁxed at 5%. Sensitivity
analyses and second order Monte-Carlo simulation were
performed. RESULTS: Life expectancy of this cohort was
32.5 years. Discounted total cost was €6,990 compared
to €14,133 without discounting. Patients spent 12.3 years
in ﬁrst line, 5.1 in second, 3.9 in third, and 3.2 in fourth,
and 5.7 without treatment. They had 1.1 laser treatments
and 1.2 surgeries on average. They were legally blind for
2.1 years on average. Increasing ﬁrst line treatment dura-
tion by 25% would reduce discounted total cost to
€6,709, or €13,368 without discounting. Patients would
stay 1.9 years more in ﬁrst line, 0.8 years less in second,
0.6 years less in third, 0.6 years less in fourth and 0.3
years less without treatment. The use of surgery and laser
would decrease by 10%. CONCLUSION: Increasing 
ﬁrst line glaucoma treatment duration is a cost saving
approach over life of a patient according to our model.
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OBJECTIVES: In order to conduct a multi-national 
retrospective chart review with the purposes of assessing
resource utilization and costs associated with disease pro-
gression in Europe, a glaucoma staging system (GSS) was
needed. To date no universally accepted GSS exists, par-
ticularly one that takes into account economic consider-
ations. We developed and tested a modiﬁed system to
allow for unambiguous stage assignment of patients expe-
riencing varied severity of disease. METHODS: A review
of currently developed GSSs was conducted and the
Bascom Palmer GSS was selected as most adaptable for
economic analyses. A modiﬁed-Delphi panel of physicians
specializing in glaucoma treatment suggested modiﬁca-
tions to the system, with the end goal of assessing the eco-
nomic impact of treating glaucoma. Three centers were
identiﬁed in each of the four participating countries:
France, Germany, Italy and U.K. Approximately 12
charts per center were selected based on the inclusion/
exclusion criteria described in the study protocol. The
revised GSS was applied on all identiﬁed charts to clas-
sify patients by disease severity. Clinical and demographic
data were obtained from the charts and national-level
ﬁnancial data were obtained from health economists in
each country. RESULTS: The ﬁnal GSS comprises six
stages based principally on visual ﬁeld parameters. End-
stage disease deﬁnition was based on poor visual acuity
and inability to perform visual ﬁelds. The staging system
was able to classify over 100 identiﬁed charts of glaucoma
patients from normal to end-stage disease, and facilitated
resource utilization abstraction by individual stage.
CONCLUSIONS: An improved GSS to track progression
was designed which allows staging of patients from his-
torical chart data. This GSS may be used to monitor long-
term progression and is a useful tool for the purposes of
assessing the economic impact of glaucoma progression.
The tool should be tested prospectively to determine its
ultimate utility in clinical practice.
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OBJECTIVE: To compare the incremental cost-utility
ratio (ICUR) of latanoprost and travoprost versus timolol
in France. METHOD: The probability to develop a visual
ﬁeld defect (VFD) was issued from a double-masked
double-dummy, phase III multi-centre clinical trial com-
paring travoprost 0.004% od, latanoprost 0.005% od
and timolol 0.5% bid, using the 2 discriminant functions
(stable and progressive patients) published by Stewart,
1993. A Markov model was constructed to reproduce the
cost and utility of a patient treated over ﬁve years, includ-
ing the following states: VFD and no VFD. Utility was
derived from Brown (2000), based on visual acuity. Direct
medical and indirect costs were estimated from a ﬁve-year
retrospective patient chart analysis. Both costs and out-
comes were discounted at a 5% rate. The economic per-
spective was the one of Society. Sensitivity analysis was
performed on the 25th to 75th percentile range of the dis-
criminant empirical distribution function. RESULTS: The
ICUR of latanoprost over timolol was €20,327/QALY
and €15,374 for travoprost. Results without discounting
were similar, €20,150 and €15,196, respectively. At the
25th percentile of the discriminant function, the ICUR
were €58,250 and €38,428 respectively and €11,262 
and €11,639 at the 75th percentile. At the median of 
the distribution function, travoprost in comparison to
latanoprost brings 0.01 QALY at a €51 additional cost.
CONCLUSION: According to our model, travoprost is a
cost-effective alternative to timolol. The additional cost
to be paid for one QALY in comparison to timolol is
lower with travoprost than with latanoprost.
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OBJECTIVE: To improve patient reported outcomes of
brimonidine 0.2% ophthalmic solution, a new formula-
tion was researched and developed. The intent was to
improve patient satisfaction and patient comfort while
maintaining patient efﬁcacy. The economic impact of
these improvements was also evaluated. METHODS:
Randomized, controlled trials were conducted in 743
patients to evaluate the original formulation vs. the new
formulation. The new formulation reduced the concen-
tration of the active ingredient from 0.2% to 0.15% and
replaced the preservative, benzalkonium chloride (BAK),
with Purite. Patient outcomes were satisfaction and
comfort level with the product. The economic evaluation
model estimated the annual cost per patient including
pharmacy and medical ofﬁce visits (including those that
may occur due to adverse events.) RESULTS: More
patients were satisﬁed with the new formulation (83%)
than the original (75%) (p < 0.05). 85% of patients
reported the new formulation was comfortable vs. 79%
for the original. Approximately 90% of the new formu-
lation patients had no reported ocular allergy vs. 84% of
the original formulation patients. Considering the addi-
tional costs associated with allergy as an additional ofﬁce
visit, the economic model estimated the cost of an allergy
patient was 36% higher than for an allergy free patient.
CONCLUSION: Patients receiving the new 0.15% refor-
mulation of brimonidine rated their treatment satisfaction
and comfort level higher than patients on the original for-
mulation while experiencing the same level of efﬁcacy.
The estimated cost savings for allergy-free patients could
have a positive impact on medical budgets.
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OBJECTIVES: High-dose vitamin supplementation
(HDVS) has recently been demonstrated to be of beneﬁt
for the prevention of progression of age-related macular
degeneration (AMD) by the investigators of the Age-
Related Eye Disease Study (AREDS), a National Eye 
Institute-sponsored randomized clinical trial. The aim of
our study was to determine the cost-utility of HDVS 
in patients with the moderately advanced form of “dry”
AMD. The analysis was performed from the perspective
of a third party-insurer who was considering adding
HDVS to their list of insured beneﬁts. METHODS:
Various decision analyses, based on Markov processing,
were performed. Our models incorporated published data
from the AREDS, our own patient-based utilities 
(n = 127) and anticipated reductions in the need for treat-
ments and services needed to treat the “wet” form of this
disease. In addition, we created a cost-utility model by
considering incremental medical costs incurred through
the use of HDVS. Various sensitivity analyses were
carried out to determine the robustness of our models.
RESULTS: Our decision analysis, based on patient-
derived utilities, demonstrated that HDVS with both
antioxidants and zinc was found to be the preferred
method of action, as it was associated with an expected
relative gain in utility of 2.9 percent. Monte Carlo simu-
lation demonstrated that the observed difference between
treatment and placebo was statistically signiﬁcant (p =
0.021). Our cost-effective model, which employed a 5%
discount rate, demonstrated that the cost per quality-
of-life adjusted year (QALY) associated with high dose
vitamin supplementation, when applied to patients with
the moderately advanced form of dry age-related macular
degeneration (group 3 or 4 disease according to the
AREDS), was $2,816.63. CONCLUSION: High-dose
vitamin supplementation of patients with the moderately
advanced form of “dry” age-related macular degenera-
